Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Non-Current Debt (2024 - 2026)

TriSalus Life Sciences has reported Non-Current Debt over the past 3 years, most recently at $33.1 million for Q1 2026.

  • For Q1 2026, Non-Current Debt rose 4.35% year-over-year to $33.1 million; the TTM value through Mar 2026 reached $33.1 million, up 4.35%, while the annual FY2025 figure was $33.0 million, 49.64% up from the prior year.
  • Non-Current Debt for Q1 2026 was $33.1 million at TriSalus Life Sciences, roughly flat from $33.0 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $33.1 million in Q1 2026 and troughed at $21.3 million in Q2 2024.
  • A 3-year average of $28.5 million and a median of $32.0 million in 2025 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 51.62% in 2025 and later increased 4.35% in 2026.
  • Year by year, Non-Current Debt stood at $22.1 million in 2024, then soared by 49.64% to $33.0 million in 2025, then increased by 0.1% to $33.1 million in 2026.
  • Business Quant data shows Non-Current Debt for TLSI at $33.1 million in Q1 2026, $33.0 million in Q4 2025, and $32.8 million in Q3 2025.